715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)

• Stephane Champiat,
• Francois-Xavier Danlos,
• Volker Kunzmann,
• Martin Wermke,
• Aude de Gassart,
• Daniel Olive,
• Patrick Brune,
• Emmanuel Valentin,
• Johann De Bono,
• Paul Frohna,
• Marina Iché,
• Maelle Mairesse,
• Celine Leparquier,
• Katrien Lemmens

Affiliations

Stephane Champiat

2Gustave Roussy Comprehensive Cancer Center, Villejuif, France

Francois-Xavier Danlos

2Gustave Roussy Comprehensive Cancer Center, Villejuif, France

Volker Kunzmann

4University Hospital Wurzburg, Wurzburg, Germany

Martin Wermke

3Technical University Dresden – NCT/UCC Early Clinical Trial Unit, Dresden, Germany

Aude de Gassart

5ImCheck Therapeutics, Marseille, France

Daniel Olive

7Institut Paoli Calmettes, INSERM UMR1068, Marseille, France

Patrick Brune

5ImCheck Therapeutics, Marseille, France

Emmanuel Valentin

5ImCheck Therapeutics, Marseille, France

Johann De Bono

1Institute of Cancer Research, London, UK, UK

Paul Frohna

5ImCheck Therapeutics, Marseille, France

Marina Iché

6ILife Consulting, Paris, France

Maelle Mairesse

5ImCheck Therapeutics, Marseille, France

Celine Leparquier

6ILife Consulting, Paris, France

Katrien Lemmens

5ImCheck Therapeutics, Marseille, France